{"id":"W4405215161","doi":"10.1016/j.eclinm.2024.102991","title":"Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial","year":2024,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; BC Cancer Agency; Cancer Care Ontario; McGill University; McGill University Health Centre; Juravinski Cancer Centre; University Health Network; Ottawa Hospital; CancerCare Manitoba; BC Studies; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences","funders":"Canadian Cancer Society Research Institute; Canadian Cancer Society; AstraZeneca","keywords":"Durvalumab; Medicine; Tremelimumab; Open label; Cancer; Internal medicine; Clinical trial; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003821997,0.001708298,0.003160625,0.0005270964,0.0004590715,0.001287546,0.001046129,0.001404835,0.00333619],"category_scores_gemma":[0.002137945,0.0007977134,0.001385665,0.0006041676,0.000956952,0.001555185,0.0008510874,0.002236562,0.0006867537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001147842,"about_ca_system_score_gemma":0.001688102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004619631,"about_ca_topic_score_gemma":0.0009831683,"domain_scores_codex":[0.9987763,0.0006203319,0.0001033172,0.0002412509,0.0000957374,0.0001630784],"domain_scores_gemma":[0.9983322,0.0002603131,0.0005159295,0.0001765923,0.000109619,0.0006054171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9461212,0.01320446,0.002868115,0.0004706193,0.0007760652,0.00008929444,0.0001063228,0.0006693131,0.008494378,0.0002005216,0.0009409295,0.02605884],"study_design_scores_gemma":[0.850555,0.1445984,0.002412186,0.00001917385,0.0002352057,0.0001079684,0.00002153488,0.0004940204,0.0005143691,0.0001460402,0.0008803742,0.0000157634],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907175,0.001804429,0.0006919844,0.0003766997,0.0001661979,0.00445219,0.0007870665,0.00005942159,0.0009446168],"genre_scores_gemma":[0.9857596,0.001291582,0.002993154,0.0007439884,0.0002729864,0.006534196,0.001228867,0.00002383796,0.001151755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003821997,"threshold_uncertainty_score":0.02021289,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06434953328348646,"score_gpt":0.4123380692197086,"score_spread":0.3479885359362221,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}